Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TECX with free AI briefings, catalyst countdowns, and dilution alerts.

TECX · Tectonic Therapeutic, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$234.7M Cash on Hand
38.7mo Cash Runway
24.6% Short Interest
$71 Analyst Target (9)
Follow TECX by email Get an email when TECX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TECX, unsubscribe in one click. Privacy

📣 What TECX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
TX000045 Hypertension, Pulmonary Phase 2 · NCT07473700 Recruiting
TX000045- Dose A Pulmonary Hypertension Phase 2 · NCT06616974 Active not recruiting
TX000045- Dose B Pulmonary Hypertension Phase 2 · NCT06616974 Active not recruiting
TX002100 Hereditary Hemorrhagic Telangiectasia (HHT) Phase 1 · NCT07863609 Not yet recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TECX holds $234.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $18.2M/quarter from operations, an estimated runway of 38.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TECX files for a raise →

👥 Who Owns TECX

Insiders 3.4% Other 5%+ holders 35.9% Institutions (162 holders) 60.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Timothy A. Springer 5%+ holder (13D) 4,313,558 21.62% 2025-04-03
FMR, LLC Institution (13F) 2,932,368 14.70% 2026-09-30
TCG Crossover Management, LLC Institution (13F) 1,204,891 6.04% 2026-09-30
Chen Yu 5%+ holder (13G) 1,169,760 5.86% 2026-02-12
VV Manager II, LLC 5%+ holder (13D) 1,028,674 5.16% 2025-02-05
Blackrock Inc. Institution (13F) 860,736 4.31% 2026-09-30
Terrance McGuire 5%+ holder (13D) 657,976 3.30% 2025-04-03
Baker Bros. Advisors, LP Institution (13F) 607,788 3.05% 2026-09-30
5AM Venture Management, LLC Institution (13F) 606,660 3.04% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 512,412 2.57% 2026-09-30
First Light Asset Management, LLC Institution (13F) 495,950 2.49% 2026-09-30
Aberdeen Group plc Institution (13F) 484,887 2.43% 2026-09-30

Share count 19,948,037 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-26
filed 2026-10-28
REICIN ALISE
Option exercise (M) 10,000 $2.38 319,078
2026-10-26
filed 2026-10-28
REICIN ALISE
Option exercise (M) 10,000 – –
2026-09-30
filed 2026-10-02
McNamara Peter
Sale (S) 536 $23.04 54,305
2026-09-25
filed 2026-10-02
REICIN ALISE
Tax withholding (F) 1,545 $23.67 309,078
2026-09-25
filed 2026-10-02
Lochner Daniel
Tax withholding (F) 520 $23.67 58,024

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full TECX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TECX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.